drugset / Trial / NCT00981201

Celecoxib as a Chemopreventive Agent in Current and Former Smokers

NCT00981201

Phase 3 Completed 219 enrolled M.D. Anderson Cancer Center
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is: * To examine the effect of celecoxib treatment on Ki-67 expression, a marker of cell proliferation, in the bronchial epithelium of current and former smokers. * To examine the toxicity associated with celecoxib administration. * To measure the effect of celecoxib treatment on arachidonic acid metabolites in the bronchial epithelium of current and former smokers.

Timeline

Start
2001-11
Primary completion
2007-07
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified 200 mg Oral
Subject Celecoxib Other / unclassified 400 mg Oral

Indications

No indication recorded.